Biotheryx's CEO on the company's protein degradation platform and CDK4/6 program that is IND cleared and will be entering the clinic

blonca9
May 16, 2024
1 min read

Leah Fung describes how Biotheryx is leveraging the E3 ligase Cereblon to enable its protein degradation, and discusses the lead CD4/6 program that recently had an IND cleared and others in the pipeline.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Biotheryx's CEO on the company's protein degradation platform and CDK4/6 program that is IND cleared and will be entering the clinic

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight